Skip to Main Content
Contribute Try STAT+ Today

A government probe into pharmaceutical price fixing widened on Thursday as nearly two dozen state attorneys general filed a lawsuit charging six generic drug companies with collusion in setting prices for two drugs.

The lawsuit alleged that between 2013 and 2015 executives from the six companies and their staffs routinely coordinated efforts to fix and maintain prices for doxycycline hyclate, a widely used antibiotic, and glyburide, a diabetes treatment. The companies named were Mylan Pharmaceuticals, Aurobindo, Citron Pharma, Heritage Pharmaceuticals, Mayne Pharma and Teva Pharmaceutical.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.